[Featured Stock] HLB Rises 4% on News of Reapplying for US Approval of Liver Cancer Drug

HLB, which has entered the FDA re-evaluation process for Rivoceranib (product name Tulbezio), developed as a first-line treatment for liver cancer, is showing strong performance.

As of 9:57 AM on the 9th, HLB is trading at 88,900 KRW, up 4.10% (3,500 KRW) from the previous trading day. The news that HLB is re-challenging FDA approval for the first-line liver cancer treatment appears to have acted as a positive factor.

According to the pharmaceutical industry, HLB will submit documents related to FDA approval for Rivoceranib as a first-line liver cancer treatment by the 20th. HLB aims to receive approval for the first-line liver cancer treatment using a combination therapy of Rivoceranib and Camrelizumab, an immuno-oncology drug developed by China’s Hansoh Pharmaceutical.

Previously, HLB’s stock price plummeted after failing to obtain FDA approval for Rivoceranib, and its transfer listing to KOSPI was also postponed.

This content was produced with the assistance of AI translation services.